Literature DB >> 8262460

Development of glucose intolerance in obese (fa/fa) Zucker rats.

R Apweiler1, P Freund.   

Abstract

Development of glucose intolerance in genetically obese (fa/fa) rats was investigated. Comparisons were made with lean (FA/?) control rats. Oral glucose tolerance tests were performed in 7-8 weeks, 9-10 weeks, 12-13 weeks and 16-17 weeks old rats. Irrespectively of age, the obese rats showed impaired glucose tolerance and insulin sensitivity compared with age-matched lean rats. While in FA/? rats only minor changes of glucose-stimulated insulin secretion and glucose tolerance were observed with progression of age, glucose intolerance in obese animals became more pronounced with aging. Obese rats older than 12-13 weeks showed no further progression of glucose intolerance. Glucose-stimulated insulin secretion increased with aging, but basal insulinemia was unaffected. Hence, we conclude that glucose intolerance and insulin resistance in genetically obese (fa/fa) rats is almost completely developed with approximately 12 weeks.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262460     DOI: 10.1055/s-2007-1002165

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.

Authors:  A Okuno; H Tamemoto; K Tobe; K Ueki; Y Mori; K Iwamoto; K Umesono; Y Akanuma; T Fujiwara; H Horikoshi; Y Yazaki; T Kadowaki
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

2.  Preventing increased blood pressure in the obese Zucker rat improves severity of stroke.

Authors:  Jessica M Osmond; James D Mintz; David W Stepp
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-23       Impact factor: 4.733

3.  Modulation of olfactory sensitivity and glucose-sensing by the feeding state in obese Zucker rats.

Authors:  Pascaline Aimé; Brigitte Palouzier-Paulignan; Rita Salem; Dolly Al Koborssy; Samuel Garcia; Claude Duchamp; Caroline Romestaing; A Karyn Julliard
Journal:  Front Behav Neurosci       Date:  2014-09-17       Impact factor: 3.558

4.  Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases.

Authors:  Longwei Zhao; Jianlou Niu; Huan Lin; Jing Zhao; Yang Liu; Zihui Song; Congshang Xiang; Xiaojie Wang; Yong Yang; Xiaokun Li; Moosa Mohammadi; Zhifeng Huang
Journal:  EBioMedicine       Date:  2019-10-17       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.